Europe Genome Editing Market

Market Introduction

The European genome editing market is divided into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the Europe genome editing market. Europe occupies a significant position in the Europe genome editing market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is expected due to growing life science research and increase in the investment for research and development.

Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have reported the highest number of positive cases and have registered the maximum number of deaths. The cell therapy instruments supply chain, which is already logistically complicated, has to face new challenges. The cell therapy instrument market has also witness some shortfall at the beginning of COVID 19 crisis owing to factors such as disruption in supply chain and demand due to lock down announced by majority of European countries. For instance, in July 2020 the UK government has allotted 100 million Euros funds to the Cell and Gene Therapy Catapult Manufacturing Innovation Centre to expedite the production of a vaccine for COVID-19 in the UK. Moreover, Stempeutics Research has filed application seeking European Commission Funding to develop cell therapy for COVID 19. The company has also entered into partnership with global consortium of cell therapy companies to gather funding for cell therapy research from European commission. Hence, Europe market is likely to show significant growth prospects during this pandemic and forecasted year.

Market Overview and Dynamics

The genome editing market in Europe is expected to grow US$ 1,487.30 million in 2021 to US$ 4,791.46 million by 2028; it is estimated to grow at a CAGR of 18.2% from 2021 to 2028. Technological developments in healthcare IT allow the use of artificial intelligence (AI) for manufacturing CRISPR Systems. Developers working in the healthcare IT domain are engaged in analyzing the processes to control and monitor all the stages of product development. The focus is to develop technologies from discovering biomarkers to clinical trials and patient monitoring. A few companies have initiated implementing their expertise to use AI for digital manufacturing. In June 2018, Celixir plc acquired Desktop Genetics to develop CRISPR-based gene editing. In August 2018, bluebird bio, Inc. and Gritstone Oncology, Inc. collaborated to develop and commercialize cell therapy products intended for cancer treatment. Under the agreement, Gritstone Oncology has utilized its proprietary EDGE artificial intelligence platform to analyze specific tumor types. EDGE AI platform has helped identify tumor-specific targets and natural T-cell receptors (TCRs) that are used as targets by bluebird bio to develop cell therapies. Further, Gritstone Oncology has utilized those identified targets to conduct development, manufacturing, and commercial processes. Thus, such innovations are expected to foster genome editing and enhance the market growth in the coming years.

Key Market Segments

In term of technological, CRISPR segment held a larger market share of the genome editing market in 2021. In term of application, genetic engineering segment held a larger market share of the genome editing market in 2021. In term of end user, pharmaceutical and biotechnology companies segment held a larger market share of the genome editing market in 2021.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the genome editing market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are THERMO FISHER SCIENTIFIC INC.; MERCK KGaA; Lonza; Horizon Discovery Group plc.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; and CRISPR Therapeutics among others.

Reasons to buy report

• To understand the Europe genome editing market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe genome editing market
• Efficiently plan M&A and partnership deals in Europe genome editing market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe genome editing market
• Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.

Europe Genome Editing Market Segmentation

Europe Genome Editing Market – By

Technology

• CRISPR
• TALEN
• Antisense
• Other

Europe Genome Editing Market – By

Application

• Cell Line Engineering
• Genetic Engineering
• Diagnostic Applications
• Drug Discovery
• Others

Europe Genome Editing Market – By

End User

• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Clinical Research Organizations (CRO's)

Europe Genome Editing Market – By

Country

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Europe Genome Editing Market – Companies Mentioned

• THERMO FISHER SCIENTIFIC INC.
• MERCK KGaA
• Lonza
• Horizon Discovery Group plc.            
• Integrated DNA Technologies         
• GenScript
• New England Biolabs
• Eurofins Scientific
• CRISPR Therapeutics

Europe Genome Editing Strategic Insights

Strategic insights for the Europe Genome Editing provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Genome Editing Report Scope

Europe Genome Editing Regional Insights

The geographic scope of the Europe Genome Editing refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.